通过天门冬氨酸（Asp）、异亮氨酸（Ile）热缩聚反应，制备了天门冬氨酸-异亮氨酸共聚物（AI），通过乙二胺（EDA）胺化，并与1，4，7，10-四氮杂环十二烷-1，4，7，10-四羧酸（DOTA）连接，再与钆离子（Gd3+）络合，合成了生物相容性大分子磁共振成像（MRI）造影剂——AI-EDA-DOTA-Gd．运用红外光谱（IR）、核磁共振（NMR）、电感耦合等离子谱（ICP）等方法对其进行结构表征，并通过弛豫性能、溶血性质、急性毒性及动物体内成像对其进行综合评价．体外弛豫结果表明，AI-EDA-DOTA-Gd的纵向弛豫效率（r1=12.6mmol-1·L·s-1）是商用造影剂Gd-DOTA（r1=5.8 mmol-1·L·s-1）的2.2倍．动物组织生理切片和溶血性实验结果说明其具有良好的生物相容性和较低的毒性．动物体内成像结果显示，AI-EDA-DOTA-Gd的最佳成像时间为30~70 min，注射AI-EDA-DOTA-Gd后的肝脏组织信号相比于未注射造影剂时增强了约（55.1±5.7）%．
李晓晶
,
湛游洋
,
薛蓉
,
裴奉奎
,
冯江华
,
祝云龙
. 氨基酸共聚物修饰的生物相容性MRI造影剂[J]. 波谱学杂志, 2016
, 33(4)
: 635
-645
.
DOI: 10.11938/cjmr20160413
A macromolecular gadolinium complex was prepared as a magnetic resonance imaging (MRI) contrast agent. An ethlendiamine-modified aspartic acid-valine copolymer was synthesized, conjugated with DOTA, and then chelated with Gd3+(AI-EDA-DOTA-Gd). T1-relaxivity of the agent (i.e., 12.6 mmol-1·L·s-1) was 2.2 times that of Gd-DOTA (i.e., 5.8 mmol-1·L·s-1). Hemolytic tests showed that the macromolecular contrast agent had good blood compatibility. Histological results demonstrated low toxicity of the agent in vivo. MRI experiments on rats demonstrated a prominent enhancement in liver after AI-EDA-DOTA-Gd injection, which persisted longer than that obtained by Gd-DOTA injection. The mean percentage enhancement in liver parenchyma was (55.1±5.7)% at 30~70 min after injection.
[1] Yang Bao-lian(杨保联). Future of ultra high field MRI in basic research and clinical applications(超高场磁共振人体成像应用研究和医学前景)[J]. Chinese J Magn Reson(波谱学杂志), 2015, 32(4):707-714.
[2] Yu Kai-chao(俞开潮), Wang Guo-ping(王国平), Ding Shang-wu(丁尚武), et al. Recent progresses in the development of contrast agents used in magnetic resonance imaging(用于磁共振成像对比增强的造影剂研发进展)[J]. Chinese J Magn Reson(波谱学杂志), 2004, 21(4):505-525.
[3] Chen Y Y, Zhu Q, Hu A G, et al. Preparation of highly efficient MRI contrast agents through complexation of cationic GdⅢ-containing metallosurfactant with biocompatible polyelectrolytes[J]. Chem Eur J, 2014, 20(39):12477-12482.
[4] Pierre V C, Allen M J, Caravan P. Contrast agents for MRI:30+years and where are we going?[J]. J Biol Inorg Chem, 2014, 19(2):127-131.
[5] Gaetano G, Gennara C, Laura M. Synthesis and characterization of novel chemical conjugates based on α,β-polyaspartylhydrazide and β-cyclodextrins[J]. Eur Polym J, 2006, 42(10):2715-2729.
[6] Yang H M, Park C W, Ahn T, et al. A direct surface modification of iron oxide nanoparticles with various poly(amino acid)s for use as magnetic resonance probes[J]. J Colloid Interf Sci, 2013, 391:158-167.
[7] Adel B, Graaf L M, Que I, et al. Contrast enhancement by lipid-based MRI contrast agents in mouse atherosclerotic plaques; a longitudinal study[J]. Contrast Media Mol I, 2013, 8(1):63-71.
[8] Xiao Yan(肖研), Zhan You-yang(湛游洋), Xue Rong(薛蓉), et al. A biocompatible gadolinium (Ⅲ)-poly (aspartic acid-co-phenylalanine) for liver magnetic resonance imaging contrast agent(一种肝脏类生物相容性氨基酸共聚物磁共振成像造影剂)[J]. Chinese J Magn Reson(波谱学杂志), 2015, 32(2):273-282.
[9] Chen X, Park R, Tohme M, et al. Micro PET and autoradiographic imaging of breast cancer alpha(v)-integrin expression using F-18-and Cu-64-labeled RGD peptide[J]. Bioconjugate Chem, 2004, 15(1):41-49.
[10] Werner E J, Datta A, Jocher C I, et al. High-relaxivity MRI contrast agents:where coordination chemistry meets medical imaging[J]. Angew Chem Int Ed Engl, 2008, 47(45):8569-8580.
[11] Yu Kai-chao(俞开潮), Lv Zhi-yong(吕志勇), Yao Yao(姚瑶), et al. Recent progress in development of bio-active MRI contrast agents(生物激活磁共振成像造影剂的研究进展)[J]. Chinese J Magn Reson(波谱学杂志), 2010, 27(3):355-368.
[12] Dekie L, Toncheva V, Dubruel P, et al. Poly-L-glutamic acid derivatives as vectors for gene therapy[J]. J Control Release, 2000, 65(1, 2):187-202.
[13] Dai L L, Liu Y K, Wang Z Q, et al. One-pot facile synthesis of PEGylated superparamagnetic iron oxide nanoparticles for MRI contrast enhancement[J]. Mater Sci Eng C Mater Biol Appl, 2014, 41:161-167.
[14] Xiao Y, Xue R, Li X J, et al. Gadolinium-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid conjugate of arabinogalactan as a potential liver-targeting magnetic resonance imaging contras tagent[J]. Carbohydr Res, 2014, 395:9-14.
[15] Sun G Y, Feng J H, Pei F K, et al. Synthesis and evaluation of novel polysaccharide-Gd-DTPA compounds as contrast agent for MRI[J]. J Magn Magn Mater, 2003, 265(2):123-129.
[16] Xiao Y, Xue R, Li X J, et al. A new biodegradable and biocompatible gadolinium(Ⅲ)-polymer for liver magnetic resonance imaging contrast agent[J]. Magn Reson Imaging, 2015, 33(6):822-828.
[17] Zhang G D, Zhang R, Melancon M P, et al. The degradation and clearance of Poly (N-hydroxypropy-L-glutamine)-DTPA-Gd as a blood pool MRI contrast agent[J]. Biomaterials, 2012, 33(2):5376-5383.
